TRICIN: Prospective Study on the Efficacy of Single Topical Trichloroacetic Acid (TCA) 85% in the Treatment of Cervical Intraepithelial Neoplasia (CIN 1/2)

NCT ID: NCT04400578

Last Updated: 2022-04-07

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: NA
• Total Enrollment: 102 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2020-02-07
• Study Completion Date: 2022-01-18

Brief Summary

Trichloroacetic acid 85% =TCA is an investigational device intended to achieve a complete histologic remission in individuals with cervical intraepithelial neoplasia (CIN) grade 1/2. The device system is to be used only in accordance with the approved Investigational Plan on subjects, who have given written informed consent.

High remission and regression rates are expected after a single topical treatment with 85% TCA. After a single topical treatment with 85% TCA for CIN 1-2 (Expected 70% or higher; null hypothesis: not higher than 55%). Regression is defined as improvement from high grade lesion (CIN 2) at baseline to low grade lesion (CIN 1) after TCA treatment. Regression from CIN 1 normal squamous epithelium after the TCA treatment is equal to remission and will be counted as a remission in combined analysis. Remission is defined as complete histologic remission of CIN back to normal squamous epithelium after the TCA treatment, i.e., no cervical dysplasia is detectable by histology or cytology after the TCA treatment. Type-specific HPV Clearance is defined as disappearance of the HPV type detected at screening.

Detailed Description

Visit and assessment Schedule:

Visit1 Screening:

• Informed Consent,
• Inclusion/Exclusion Criteria,
• Medical History,
• Gynecological Examination
• Cytology
• HPV Test
• Colposcopy
• Biopsy
• VAS (Visual analog scale)
• Pregnancy test

Visit 2 Treatment Day with TCA 85%:

• Colposcopy
• TCA Treatment
• VAS
• Pregnancy test

Visit 3, Control 1, Week 10-14:

• Cytology
• HPV Test
• Colposcopy
• Biopsy
• 4-quadrant biopsy
• ECC
• Adverse event monitoring If there is no sign of CIN during the colposcopic examination 10-14 weeks a 4-quadrant biopsy and a ECC are performed

Visit 4, Control 2, Week 22-26:

• Cytology
• HPV Test
• Colposcopy
• Biopsy
• 4-quadrant biopsy
• ECC
• Adverse event monitoring
• Pregnancy test If there is no sign of CIN during the colposcopic examination 22-26 weeks after the TCA treatment, a 4-quadrant biopsy and a ECC are performed.

Visit 5, EOS , Week 24-30:

• Results Discussion

Conditions

Cervical Intraepithelial Neoplasia Grade 1; Cervical Intraepithelial Neoplasia Grade 2

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

TRICIN

If a patient is eligible

1. local anesthesia with Xylocain 10% with a pump spray for a period of 10 seconds- one time application

2. Procain 2%: local anesthesia with a swab for a period of 10 seconds- one time application

3. Trichloroacetic acid TCA 85% 1-2 ml with soaked swab for max. 2 minutes -one time application

Group Type: EXPERIMENTAL

Trichloroacetic acid 85% (TCA)

Intervention Type: DEVICE

Purpose and scope of Medical Device: Treatment and relief of a disease. Application to cervical intraepithelial neoplasia with a cotton swab.TCA is an investigational device intended to achieve a complete histologic remission in individuals with cervical intraepithelial neoplasia (CIN) grade 1/2.

Interventions

Trichloroacetic acid 85% (TCA)

Purpose and scope of Medical Device: Treatment and relief of a disease. Application to cervical intraepithelial neoplasia with a cotton swab.TCA is an investigational device intended to achieve a complete histologic remission in individuals with cervical intraepithelial neoplasia (CIN) grade 1/2.

Intervention Type: DEVICE

Eligibility Criteria

Inclusion Criteria

• Histologically proven CIN 1/2
• adequate colposcopy (i.e. fully visible transformation zone and margins of any visible lesion)
• positive HPV test
• conducted negative pregnancy test
• women aged 18 to 50 years
• written informed consent

Exclusion Criteria

• inadequate colposcopy
• negative or missing biopsy
• cytology results indicating invasive disease (PAP V)
• if the cervical lesion recedes into the endocervical canal
• pregnancy
• any medical circumstance considered relevant for proper performance of the study, or risks to the patient, at the discretion of the investigator

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 50 Years
• Eligible Sex: FEMALE
• Accepts Healthy Volunteers: No

Sponsors

Medical University of Vienna

OTHER

Sponsor Role: collaborator

Krankenhaus Barmherzige Schwestern Linz

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Lukas Hefler, MD

Role: PRINCIPAL_INVESTIGATOR

Krankenhaus Barmherzige Schwestern Linz

Locations

Department of gynaecology, Ordensklinikum Linz Ges.m.b.H, Barmherzige Schwestern

Linz, , Austria

Countries

Austria

Other Identifiers

EKS 48/19

Identifier Type: -

Identifier Source: org_study_id